Wikidata

(Q65387121)

English

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

clinical trial

In more languages

Statements

title
A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) (English)
0 references
country
Austria
0 references
Belgium
0 references
France
0 references
Germany
0 references
Spain
0 references
United Kingdom
0 references
start time
November 2006
0 references
end time
November 2008
0 references
number of participants
106
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q65387121&oldid=1858412937"